EMAIL THIS PAGE TO A FRIEND

American journal of hematology

Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.


PMID 24757092

Abstract

A major limitation to improved outcomes in acute myelogenous leukemia (AML) is relapse resulting from leukemic cells that persist at clinical remission. Regulatory T cells (Tregs), which are increased in AML patients, can contribute to immune evasion by residual leukemic cells. Tumor necrosis factor (TNF), a pro-inflammatory cytokine present at high levels within patients, can induce TNF receptor-2 (TNFR2) expression on Tregs. We hypothesized that since TNFR2 is required for Treg stabilization and TNFR2+ Tregs are potent suppressors, targeting TNFR2+ Tregs may restore the effectiveness of immune-surveillance mechanisms. In this pilot study, we report AML patients in clinical remission have substantially increased levels of TNFR2+ T cells, including TNFR2+ Tregs and impaired effector CD4 T cell function with reduced IL-2 and IFNγ production. The immunomodulatory drug, lenalidomide, and the demethylating agent, azacitidine have been moderately successful in treating AML patients, but their combined effects on TNFR2+ T cells, including Tregs are currently unknown. Our data indicates that although treatment with lenalidomide and azacitidine increased cytokine production by effector T cells in all patients, durable clinical remissions may be observed in patients with a concomitant reduction in TNFR2+ T cells and TNFR2+ Tregs. In vitro studies further demonstrated that lenalidomide can reduce TNFR2 expression and can augment effector cytokine production by T cells, which can be further enhanced by azacitidine. These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2501381
Anti-Cd28 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501674
Anti-CD28 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405583
Anti-CD28 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
C7831 Anti-CD28 antibody, Mouse monoclonal, clone CD28.2, purified from hybridoma cell culture
HPA004252
Anti-CD4 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA004472
Anti-CD4 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
C6612 Anti-CTLA-4 antibody produced in goat, affinity isolated antibody, lyophilized powder
GW21075 Anti-CXCR4 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
C3116
Anti-CXCR4 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500383
Anti-CXCR4 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1405588
Anti-ENTPD1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA014067
Anti-ENTPD1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4503659
Anti-ENTPD1 antibody produced in rabbit, affinity isolated antibody
SAB2107618
Anti-ENTPD1 antibody produced in rabbit, affinity isolated antibody
SAB1306189
ANTI-IDDM12(N-TERMINAL) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA017357
Anti-NT5E antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2501726
Anti-Tnfrsf1b antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406540
Anti-TNFRSF1B antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA004796
Anti-TNFRSF1B antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1411354
Anti-TNFRSF1B antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
C9979 Monoclonal Anti-CD152 antibody produced in mouse, ~1 mg/mL, clone AS32, purified immunoglobulin, buffered aqueous solution
SAB4700360 Monoclonal Anti-CD25 antibody produced in mouse, clone MEM-181, purified immunoglobulin, buffered aqueous solution
SAB4700365 Monoclonal Anti-CD25 antibody produced in mouse, clone MEM-140, purified immunoglobulin, buffered aqueous solution
SAB1305503
MONOCLONAL ANTI-CD25 antibody produced in mouse, clone 7G7B6, crude ascites, buffered aqueous solution
SAB4700135 Monoclonal Anti-CD28 antibody produced in mouse, low endotoxin, clone CD28.2, purified immunoglobulin, buffered aqueous solution
SAB4700739 Monoclonal Anti-CD28 antibody produced in mouse, clone JJ319, purified immunoglobulin, buffered aqueous solution
SAB4700751
Monoclonal Anti-CD28 antibody produced in mouse, clone CD28.2, purified immunoglobulin, buffered aqueous solution
SAB4700059
Monoclonal Anti-CD4 , (N-terminal) antibody produced in mouse, clone MEM-241, purified immunoglobulin, buffered aqueous solution
C1805 Monoclonal Anti-CD4 antibody produced in mouse, clone Q4120, purified immunoglobulin, buffered aqueous solution
SAB4700054 Monoclonal Anti-CD4 antibody produced in mouse, clone MEM-16, purified immunoglobulin, buffered aqueous solution